TW366345B - Substituted liposaccharides useful in the treatment and prevention of endotoxemia - Google Patents

Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Info

Publication number
TW366345B
TW366345B TW085106735A TW85106735A TW366345B TW 366345 B TW366345 B TW 366345B TW 085106735 A TW085106735 A TW 085106735A TW 85106735 A TW85106735 A TW 85106735A TW 366345 B TW366345 B TW 366345B
Authority
TW
Taiwan
Prior art keywords
endotoxemia
treatment
prevention
useful
substituted liposaccharides
Prior art date
Application number
TW085106735A
Other languages
English (en)
Chinese (zh)
Inventor
William J Christ
Daniel P Rossignol
Seiichi Kobayashi
Tsutomu Kawada
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23833509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW366345(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of TW366345B publication Critical patent/TW366345B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
TW085106735A 1995-06-05 1996-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia TW366345B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/461,675 US5750664A (en) 1995-06-05 1995-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Publications (1)

Publication Number Publication Date
TW366345B true TW366345B (en) 1999-08-11

Family

ID=23833509

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085106735A TW366345B (en) 1995-06-05 1996-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Country Status (21)

Country Link
US (8) US5681824A (OSRAM)
EP (1) EP0853627B1 (OSRAM)
JP (3) JP4009318B2 (OSRAM)
KR (1) KR100416335B1 (OSRAM)
CN (1) CN1067082C (OSRAM)
AT (1) ATE258185T1 (OSRAM)
AU (1) AU707779C (OSRAM)
CA (1) CA2223140C (OSRAM)
DE (1) DE69631376T2 (OSRAM)
DK (1) DK0853627T3 (OSRAM)
ES (1) ES2214543T3 (OSRAM)
HU (1) HU221342B1 (OSRAM)
IL (2) IL122251A0 (OSRAM)
MX (1) MX9709502A (OSRAM)
NO (1) NO310239B1 (OSRAM)
NZ (1) NZ312299A (OSRAM)
PT (1) PT853627E (OSRAM)
RU (1) RU2170738C2 (OSRAM)
TW (1) TW366345B (OSRAM)
WO (1) WO1996039411A1 (OSRAM)
ZA (1) ZA964666B (OSRAM)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
ES2242226T3 (es) * 1996-07-03 2005-11-01 Eisai Co., Ltd. Composiciones que contienen analogos del lipido a y procedimiento parasu preparacion.
WO2000013029A1 (en) * 1998-09-01 2000-03-09 Eisai Co., Ltd Method for evaluating lipid a analog-containing injections
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
EP1158990B1 (en) * 1999-01-14 2007-10-17 Eisai R&D Management Co., Ltd. Use of e5564 for the treatment of sepsis by intravenous infusion
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
HK1040519A1 (en) * 1999-02-10 2002-06-14 Sankyo Company, Limited Ether type lipid a1-carboxylic acid analogues
US20050101549A1 (en) * 2000-01-14 2005-05-12 Melvyn Lynn Prevention and treatment of endotoxemia and related complications associated with surgery
AU2001229479A1 (en) * 2000-01-14 2001-07-24 Eisai Co. Ltd. Prevention and treatment of endotoxemia and related complications associated with surgery
AU3850701A (en) 2000-02-18 2001-08-27 Eisai Co Ltd Micelles
US6861512B2 (en) 2000-03-01 2005-03-01 Eisai Co., Ltd. Separation of olefinic isomers
US20030105033A1 (en) * 2000-06-09 2003-06-05 Rossignol Daniel P. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
EP1363642A4 (en) * 2000-06-09 2005-02-02 Eisai Co Ltd ADMINISTRATION OF ANTI-ENDOTOXIN DRUG BY INJECTION OF A BOWL OR BY INTERMITTENT INTRAVENOUS INFUSION
WO2002088072A1 (en) * 2001-04-23 2002-11-07 Eisai Co., Ltd. Process for preparation of alkylene compounds
WO2002088062A1 (en) * 2001-04-23 2002-11-07 Eisai Co., Ltd. Process for preparation of alcohol derivatives
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
JP4366081B2 (ja) * 2001-05-22 2009-11-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 高度に精製されたアンチエンドトキシン化合物
DE10125179A1 (de) * 2001-05-23 2002-12-05 Laves Ralph Georg Verwendung von LPS zur Behandlung intestinaler Entzündungsprozesse
AU2002323106A1 (en) * 2001-08-10 2003-02-24 Eisai Co., Ltd. Treatment and prevention of heat shock protein-associated diseases and conditions
US7727974B2 (en) * 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
WO2003050137A2 (en) * 2001-12-11 2003-06-19 David Schwartz Toll-like receptor 4 mutations
AU2002950657A0 (en) * 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
AU2003289493A1 (en) * 2002-12-24 2004-07-22 Mochizuki, Takashi Lipid a analogues having glucose as the right sugar
PT1589934E (pt) * 2003-01-06 2016-01-26 Corixa Corp Determinados compostos de fosfato de aminoalquil glucosaminida e seu uso
EP1587830B1 (en) * 2003-01-28 2009-07-08 Academisch Ziekenhuis Leiden Peptide inhibitors of toxins derived from ll-37
US7906633B2 (en) * 2003-02-20 2011-03-15 Eisai R&D Management Co., Ltd. Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof
RU2005130771A (ru) * 2003-03-05 2006-01-27 Эйсай Ко., Лтд. (JP) Композиции и способы профилактики и лечения эндотоксин-связанных заболеваний и состояний
WO2005027826A2 (en) * 2003-07-14 2005-03-31 Eisai, Co, Ltd. Methods and treating severe acute respiratory syndrome
WO2005059517A2 (en) 2003-12-16 2005-06-30 University Of Massachusetts Toll-like receptor assays
WO2005066193A1 (ja) * 2004-01-08 2005-07-21 Sankyo Company, Limited 左糖グルコースリピドa類縁体
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CN103285392A (zh) 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
US20100015125A1 (en) * 2005-06-17 2010-01-21 University Of Rochester Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion
JP5118968B2 (ja) * 2005-08-31 2013-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 リピッドａ類縁体の製造方法
WO2007026675A1 (ja) * 2005-08-31 2007-03-08 Eisai R & D Management Co., Ltd. リピッドａ類縁体の製造方法
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
WO2008062842A1 (fr) 2006-11-22 2008-05-29 Eisai R & D Management Co., Ltd. Sel de sodium de disaccharide et ses méthodes de production et d'utilisation
JP5244608B2 (ja) * 2006-11-22 2013-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 二糖類化合物のナトリウム塩及びその製造方法並びにその使用
AP2752A (en) 2006-11-23 2013-09-30 Cadila Pharmaceuticals Ltd Poly-TLR antagonist
WO2011035026A1 (en) * 2009-09-16 2011-03-24 Heidi Ehrentraut Methods for treating myocardial disorders
WO2011038537A1 (zh) * 2009-09-29 2011-04-07 上海南方基因科技有限公司 败血症以及败血症休克的预测、预防和治疗方法及试剂盒
GB201013785D0 (en) 2010-08-17 2010-09-29 Ucl Business Plc Treatment
JP2012246470A (ja) 2011-05-31 2012-12-13 Sharp Corp 半導体ナノ粒子の製造方法、半導体ナノ粒子、ならびにこれを用いた蛍光体
HK1203474A1 (en) * 2011-12-22 2015-10-30 Nanoco Technologies Limited Surface modified nanoparticles
BR112014024139A8 (pt) 2012-03-28 2018-01-16 Univ Maryland administração de eritoran ou sais farmaceuticamente aceitáveis do mesmo para tratar infecções de ortomixovírus
WO2014113048A1 (en) * 2013-01-18 2014-07-24 Loma Linda University Compositions and methods for diagnosing and treating sepsis
WO2015006740A2 (en) 2013-07-11 2015-01-15 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
US9584991B1 (en) * 2014-06-19 2017-02-28 Isaac S. Daniel Method of communicating and accessing social networks using interactive coded messages
EP3436467B1 (en) * 2016-03-30 2025-08-06 Ayuvis Research, Inc. Beta-anomer-saccharides for use in the treatment of sepsis, septic shock, septicemia, burn or wound infection
US10570074B2 (en) 2016-09-14 2020-02-25 Genomatica, Inc. 1,3-fatty diol compounds and derivatives thereof
EP3512508B1 (en) * 2016-09-16 2022-03-16 Eisai R&D Management Co., Ltd. Method of use of eritoran as a tlr4 antagonist for treatment of ebola and marburg disease
BR112021010717A2 (pt) * 2018-12-17 2021-08-31 Eisai R&D Management Co., Ltd. Formulação que compreende lipossomas
WO2021207218A1 (en) 2020-04-06 2021-10-14 Eisai R&D Management Co., Ltd. Treatment of nidovirales infection with eritoran
CN113527396B (zh) * 2020-04-17 2024-02-02 上海医药工业研究院 一种疫苗佐剂mpla的中间体、合成及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495346A (en) * 1981-03-30 1985-01-22 Wisconsin Alumni Research Foundation Method of preparing a disaccharide
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5066794A (en) * 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
JPS6153295A (ja) * 1984-08-24 1986-03-17 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体
HU199494B (en) * 1985-06-28 1990-02-28 Sandoz Ag Process for producing new saccharides and pharmaceutical compositions comprising same
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
JP2839916B2 (ja) * 1989-10-20 1998-12-24 三共株式会社 リピドａ３位エーテル類縁体
PT94481B (pt) 1989-12-11 1997-02-28 Sankyo Co Processo para a preparacao de analogos de lipidos a tendo imunoactividade e actividade anti-tumoral
JP2847319B2 (ja) 1990-05-18 1999-01-20 イビデン株式会社 電子部品搭載用多層ボンディング基板
JP3040847B2 (ja) 1990-06-22 2000-05-15 三共株式会社 リピドｘ類縁体
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
JP3135990B2 (ja) 1992-07-31 2001-02-19 沖電気工業株式会社 パリティ付加回路
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
CN1055093C (zh) * 1993-11-17 2000-08-02 实验室奥姆公司 葡糖胺二糖类、其制备方法和用途、以及含有这些二糖的药物组合物
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
JP4235193B2 (ja) 2005-06-07 2009-03-11 日本電信電話株式会社 イベント履歴蓄積装置、イベント情報検証装置、イベント履歴蓄積方法、イベント情報検証方法およびイベント情報処理システム

Also Published As

Publication number Publication date
AU6380296A (en) 1996-12-24
US20020028927A1 (en) 2002-03-07
JP2007269812A (ja) 2007-10-18
CN1192216A (zh) 1998-09-02
HUP9802662A3 (en) 1999-06-28
NO975644L (no) 1998-02-04
RU2170738C2 (ru) 2001-07-20
US6184366B1 (en) 2001-02-06
US20080214802A1 (en) 2008-09-04
CN1067082C (zh) 2001-06-13
NO310239B1 (no) 2001-06-11
US5750664A (en) 1998-05-12
US20030144503A1 (en) 2003-07-31
NO975644D0 (no) 1997-12-04
US7994154B2 (en) 2011-08-09
WO1996039411A1 (en) 1996-12-12
CA2223140A1 (en) 1996-12-12
PT853627E (pt) 2004-05-31
JPH11506793A (ja) 1999-06-15
US7737129B2 (en) 2010-06-15
JP4009318B2 (ja) 2007-11-14
US20100227835A1 (en) 2010-09-09
JP4712001B2 (ja) 2011-06-29
DE69631376T2 (de) 2004-11-11
IL122251A0 (en) 1998-04-05
US5935938A (en) 1999-08-10
KR19990022104A (ko) 1999-03-25
IL149971A (en) 2010-04-29
AU707779B2 (en) 1999-07-22
ATE258185T1 (de) 2004-02-15
DE69631376D1 (de) 2004-02-26
HU221342B1 (en) 2002-09-28
ES2214543T3 (es) 2004-09-16
EP0853627B1 (en) 2004-01-21
HUP9802662A2 (hu) 1999-05-28
KR100416335B1 (ko) 2004-07-27
EP0853627A1 (en) 1998-07-22
ZA964666B (en) 1997-03-11
NZ312299A (en) 1999-08-30
CA2223140C (en) 2008-08-05
US5681824A (en) 1997-10-28
JP2011121970A (ja) 2011-06-23
MX9709502A (es) 1998-10-31
EP0853627A4 (en) 1998-10-07
DK0853627T3 (da) 2004-06-01
AU707779C (en) 2001-12-06

Similar Documents

Publication Publication Date Title
TW366345B (en) Substituted liposaccharides useful in the treatment and prevention of endotoxemia
ZA965887B (en) Improved cement admixture product.
MX9800625A (es) Marcfortinas y paraherquamidas antiparasitarias.
EP0674455A4 (en) Multistation transmitting method and receiver therefor.
PL316658A1 (en) Novel application of serotonin antagonists
IL131332A0 (en) Methods and products for analyzing polymers
FI960780A0 (fi) Nolla intermediaarinen frekvenssivastaanotin
GB9612514D0 (en) Novel process
EP0754041A4 (en) NOVEL PHENALKYLAMINES AND SUBSTITUTED TRYPTAMINES, AND RELATED COMPOUNDS
US5805582B1 (en) Home personal communications system
ZA974084B (en) Novel α-glucuronidases, production hereof and their uses.
ZA966757B (en) Novel compounds and process.
ZA969721B (en) Method of treating sepsis.
AU2160697A (en) Nsaids in the treatment of pruritus
HU9402646D0 (en) Anomere fluoro-ribosyl-amines
HUT69373A (en) N-substituted 2-azetidinones, as intermediates in novel process of n-ansubstituted 2-azetidinones
GB9515850D0 (en) Broad specificity antibodies
ZA975061B (en) Manufacture of articles.
AU115632S (en) Door handle
HU9600288D0 (en) Bihari csipoes variety of horse-radish (armoratia l.)
HU9600287D0 (en) Bihari delikatesz variety of horse-radish (armoratia l.)
GB9412912D0 (en) Sex reversal enzyme
AU1143P (en) NECTA ZEE Prunus persica var. nucipersica
PL101899U1 (en) Camping chamber-pot
KR970003482U (ko) 무선호출수신기의 엘.씨.디 홀더구조

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent